ReviewClinical microbiology reviews2004
Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.
Review in Clinical microbiology reviews, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
132 citing papers in PubMed, 353 citations in OpenAlex.
- Oral Candida in Patients with Fixed Orthodontic Appliance: In Vitro Combination Therapy.BioMed research international · 2017Trial
- The effect of eating sea cucumber jelly on Candida load in the oral cavity of elderly individuals in a nursing home.Marine drugs · 2013Trial
- Antifungal Potential of Peptide-Enriched Fractions Isolated from Capsicum frutescens Seeds Against Yeasts of the Genus Candida.Probiotics and antimicrobial proteins · 2026Article
- Antifungal activities and toxicity studies of water-soluble non-steroidal analgesic salts.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Candicidal Effect of a Nanoemulsion Based on the Essential Oil of the Medicinal PlantPharmaceuticals (Basel, Switzerland) · 2026Article
- Emerging trends and structure-activity insights of Schiff base-lanthanide complexes as antibacterial agents.RSC advances · 2026Review
- International consensuses and guidelines on diagnosing and managing fungal endophthalmitis by the Asia-Pacific Vitreo-retina Society (APVRS), the Academy of the Asia-Pacific Professors of Ophthalmology (AAPPO), and the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII).Eye and vision (London, England) · 2025Review
- Benzoylselenoureas: A Novel Dual-Action Inhibitor Targeting Fungal Growth and Urease Activity inACS omega · 2025Article
- Bixin fromACS omega · 2025Article
- Unlocking the Potential of Brazilian Plant Terpenes to Combat Antimicrobial Resistance.ACS bio & med chem Au · 2025Review
- From Bench to Application: Evaluating the In Vitro and In Vivo Efficacy of a Polyhexamethylene Biguanide and Cross-Linked Hyaluronic Acid-Based Antiseptic Solution.Journal of clinical medicine · 2025Article
- Article
- Unveiling the Potential of Protein-Based Sustainable Antibacterial Materials.Probiotics and antimicrobial proteins · 2025Review
- Thiazole Derivatives as Promising Candidates for Cryptococcosis Therapy.ACS infectious diseases · 2025Article
- Menthol-thymol NADES as a fungicidal and chemosensitizing agent against multidrug-resistantFrontiers in pharmacology · 2025Article
- An In Vitro Evaluation of Industrial Hemp Extracts Against the Phytopathogenic BacteriaMolecules (Basel, Switzerland) · 2024Article
- A Comprehensive Review on Bioactive Molecules and Advanced Microorganism Management Technologies.Current issues in molecular biology · 2024Review
- Diverse antifungal potency of terbinafine as a therapeutic agent against Exophiala dermatitidis in vitro.Scientific reports · 2024Article
- Effect of Java plum (Open veterinary journal · 2024Article
- Otilonium Bromide Exhibits Potent Antifungal Effects by Blocking Ergosterol Plasma Membrane Localization and Triggering Cytotoxic Autophagy in Candida Albicans.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
72 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In certain unique clinical settings, the ability of the antimicrobial agent administered to kill the pathogen outright may be quite important. These situations invariably involve infection of a site not easily accessed by host defenses and/or of a structure with essential anatomic or physiologic function such as the heart (endocarditis), central nervous system (meningitis), or bone (osteomyelitis). Likewise, infections in immunosuppressed hosts, especially those who are neutropenic, are often thought to require microbicidal therapy. Proof of the cidal nature of an antimicrobial agent in vitro is tedious, complex, and fraught with error. Although several methods for assessing in vitro bactericidal activity have been standardized (NCCLS M26-A and M21-A), the clinical relevance of these determinations is questionable and the tests are performed infrequently in most laboratories. Most of the clinical data supporting the need for microbicidal therapy and testing have focused on bacterial infections. However, given the fact that most serious fungal infections occur in profoundly immunosuppressed individuals, it is generally assumed that a cidal regimen would be preferable in that setting as well. In view of this clinical concern and the perceived need to assess the fungicidal activity of a variety of agents, we considered that it would be useful to review what is known about the issues and problems in assessing bactericidal activity and the clinical utility of such measurements. Following this review, we discuss the issue of how one defines fungicidal activity in vitro and in vivo and how feasible it might be to determine the fungicidal activity of organism-drug combinations for purposes of both drug development and clinical care. Proposed methods for fungal time-kill determinations and minimal fungicidal concentration determinations are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.